Isabel Sevilla

2.3k total citations
83 papers, 1.4k citations indexed

About

Isabel Sevilla is a scholar working on Oncology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Isabel Sevilla has authored 83 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 40 papers in Epidemiology and 29 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Isabel Sevilla's work include Neuroendocrine Tumor Research Advances (38 papers), Lung Cancer Research Studies (35 papers) and Neuroblastoma Research and Treatments (26 papers). Isabel Sevilla is often cited by papers focused on Neuroendocrine Tumor Research Advances (38 papers), Lung Cancer Research Studies (35 papers) and Neuroblastoma Research and Treatments (26 papers). Isabel Sevilla collaborates with scholars based in Spain, United Kingdom and United States. Isabel Sevilla's co-authors include Rocio García‐Carbonero, Jaume Capdevila, Àlex Teulé, Emilio Alba, Daniel Castellano, Enrique Grande, Paula Jiménez‐Fonseca, Vicente Alonso, Ignacio Durán and Javier Sastre and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Isabel Sevilla

77 papers receiving 1.3k citations

Peers

Countries citing papers authored by Isabel Sevilla

Since Specialization

Citations

This map shows the geographic impact of Isabel Sevilla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabel Sevilla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabel Sevilla more than expected).

Fields of papers citing papers by Isabel Sevilla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabel Sevilla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabel Sevilla. The network helps show where Isabel Sevilla may publish in the future.

Co-authorship network of co-authors of Isabel Sevilla

This figure shows the co-authorship network connecting the top 25 collaborators of Isabel Sevilla. A scholar is included among the top collaborators of Isabel Sevilla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabel Sevilla. Isabel Sevilla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Data from Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914) 2025 ·DIGITAL.CSIC (Spanish National Research Council (CSIC)) ·(unknown), Jorge Hernando, Javier Molina‐Cerrillo, (unknown), Rocio García‐Carbonero, Àlex Teulé, Ana Custodio, Paula Jiménez‐Fonseca, Carlos López, Cinta Hierro, Alberto Carmona‐Bayonas, Vicente Alonso Orduña, Marta Llanos, Isabel Sevilla, (unknown), Teresa Alonso‐Gordoa, Inmaculada Gallego, (unknown), (unknown), Enrique Grande	0
2	Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914) 2025 ·Clinical Cancer Research ·(unknown), Jorge Hernando, Javier Molina‐Cerrillo, (unknown), Rocio García‐Carbonero, Àlex Teulé, Ana Custodio, Paula Jiménez‐Fonseca, Carlos López, Cinta Hierro, Alberto Carmona‐Bayonas, Vicente Alonso Orduña, Marta Llanos, Isabel Sevilla, (unknown), Teresa Alonso‐Gordoa, Inmaculada Gallego, (unknown), (unknown), Enrique Grande	0
3	1150P Search for biomarkers to personalize treatment with streptozotocin plus 5-fluorouracil or everolimus in patients with advanced pancreatic neuroendocrine tumors: The randomized phase III SEQTOR trial (GETNE-1206) 2024 ·Annals of Oncology ·(unknown), Alfonso Scarpa, Rita T. Lawlor, Anguraj Sadanandam, (unknown), Merete Krogh, Àlex Teulé, (unknown), Heinz‐Josef Klümpen, Birgit Cremer, Isabel Sevilla, (unknown), (unknown), J-P. Metges, N.S. Reed, J. Schrader, (unknown), Marino Venerito, (unknown), (unknown)	2
4	1142O Multivariable analysis of streptozotocin plus 5-fluorouracil and everolimus sequences in advanced pancreatic neuroendocrine tumor patients: The SEQTOR trial (GETNE-1206) 2024 ·Annals of Oncology ·(unknown), (unknown), Merete Krogh, Àlex Teulé, (unknown), Heinz‐Josef Klümpen, Birgit Cremer, Isabel Sevilla, (unknown), (unknown), J-P. Metges, N.S. Reed, J. Schrader, Silvia Bozzarelli, (unknown), (unknown), (unknown), Marino Venerito, (unknown), Rafaela Soler	1
5	Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913) 2024 ·Nature Communications ·María Carmen Riesco Martínez, Jaume Capdevila, Vicente Alonso, Paula Jiménez‐Fonseca, Àlex Teulé, Enrique Grande, Isabel Sevilla, Marta Benavent, Teresa Alonso‐Gordoa, Ana Custodio, (unknown), Jorge Hernando, Eduardo Polo, (unknown), (unknown), (unknown), (unknown), Beatriz Soldevilla, Rocio García‐Carbonero	10
6	Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A 2023 ·Signal Transduction and Targeted Therapy ·Javier Martín‐Broto, Jerónimo Martínez-García, David S. Moura, Andrés Redondo, Antonio Gutiérrez, Antonio López–Pousa, Javier Martínez‐Trufero, Isabel Sevilla, Robert Díaz Beveridge, (unknown), Amancio Carnero, Marco Pérez, David Marcilla, Jesús García‐Foncillas, Pablo Romero, (unknown), (unknown), Iván Arribas, Nadia Hindi	15
7	Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial 2021 ·The Oncologist ·Enrique Grande, Cristina Rodríguez‐Antona, Carlos López, Teresa Alonso‐Gordoa, Marta Benavent, Jaume Capdevila, Àlex Teulé, Ana Custodio, Isabel Sevilla, Jorge Hernando, Pablo Gajate, Javier Molina‐Cerrillo, Juan J. Díez, María Santos, Javier Lanillos, Rocio García‐Carbonero	16
8	Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial 2021 ·The Lancet Oncology ·Thierry André, Mayur M. Amonkar, Josephine M. Norquist, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J.A. Punt, Denis Smith, Rocio García‐Carbonero, Isabel Sevilla, Christelle de la Fouchardière, Fernando Rivera, Élena Elez, Luis A. Díaz, Takayuki Yoshino, Eric Van Cutsem, Ping Yang, Mohammed Z.H. Farooqui, Dung T. Le	135
9	1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601) 2020 ·Annals of Oncology ·Jaume Capdevila, Àlex Teulé, Carlos López, Rocio García‐Carbonero, Marta Benavent, Ana Custodio, Antonio Cubillo, Vicente Alonso, Teresa Alonso Gordoa, Alberto Carmona‐Bayonas, Guillermo Crespo, Montserrat Blanco-Codesido, Paula Jiménez‐Fonseca, A. Viúdez, (unknown), Isabel Sevilla, Marta Llanos, Ángel Segura, (unknown), José Luís Zamora Manzano	37
10	VITAL phase 2 study: Upfront 5‐fluorouracil, mitomycin‐C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09‐02) 2019 ·Cancer Medicine ·Jaime Feliú, Rocio García‐Carbonero, Jaume Capdevila, (unknown), (unknown), Carlos López, Pilar García‐Alfonso, (unknown), Isabel Sevilla, L. Cerezo, Carles Conill, (unknown), (unknown), Ismael Ghanem, Marta Martín-Richard, Miriam López-Gómez, Ana León, (unknown), Teresa de Souza Fernandez, Joan Maurel	8
11	SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018) 2018 ·Clinical & Translational Oncology ·Encarnación González‐Flores, Rafael Serrano del Rosal, Isabel Sevilla, A. Viúdez, Jorge Barriuso, Marta Benavent, Jaume Capdevila, (unknown), Carlos López, Rocio García‐Carbonero	13
12	Expression and Prognostic Value of Oestrogen Receptor Beta in Colorectal Cancer 2017 ·Pathology & Oncology Research ·Elísabeth Pérez-Ruiz, Antonio Rueda, (unknown), Francisco Rivas‐Ruiz, Esperanza Torres, Vanesa de Luque, Martina Álvarez, Isabel Sevilla, Maximino Redondo, (unknown), Emilio Alba, Lorenzo Alonso	3
13	Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma 2017 ·International Journal of Colorectal Disease ·Fernando Rivera, Meinolf Karthaus, J. Randolph Hecht, Isabel Sevilla, Frédéric Forget, Gianpiero Fasola, Jean-Luc Canon, Xuesong Guan, Gaston Demonty, Lee S. Schwartzberg	79
14	SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016) 2016 ·Clinical & Translational Oncology ·Andrés Poveda, Virginia Martínez, César Serrano, Isabel Sevilla, María José Lecumberri, Robert Díaz Beveridge, Anna Estival, David Vicente, (unknown), Javier Martín‐Broto	16
15	Second primary malignancies in patients with neuroendocrine tumors 2014 ·Clinical & Translational Oncology ·(unknown), Rafael Serrano del Rosal, (unknown), (unknown), Marc Bolaños, Encarnación González‐Flores, Isabel Sevilla	5
16	KIT, DOG1, PDGFR, and IGFR1 gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients. 2011 ·Journal of Clinical Oncology ·Javier Martín‐Broto, Xavier García del Muro, A Gutiérrez, Javier Martínez‐Trufero, Teresa Serrano, (unknown), Núria Laínez, Isabel Sevilla, (unknown), (unknown), Luís Ortega, Andrés Poveda, Maria E. Ramirez, Ricardo Cubedo, José Antonio López‐Guerrero	0
17	Prognostic value of serum angiogenic activity in colorectal cancer patients 2007 ·Journal of Cellular and Molecular Medicine ·(unknown), Ana R. Quesada, Isabel Sevilla, (unknown), Miguel Ángel Medina, (unknown), (unknown), Francisca Ríus, (unknown), Emilio Alba	10
18	Phase II Study of Weekly Irinotecan (CPT-11) as Second-Line Treatment of Patients with Advanced Colorectal Cancer 2003 ·Medical Oncology ·Javier Cassinello, (unknown), (unknown), (unknown), (unknown), (unknown), Uriel Bohn, Isabel Sevilla, (unknown), (unknown), R. Pérez-Carrión, José Luis Fernández, (unknown)	7
19	Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer 2002 ·Lung Cancer ·José María Viéitez, (unknown), (unknown), M. González‐Barón, (unknown), J. R. Mel, Ricardo Rodríguez, Manuel Constenla, (unknown), (unknown), (unknown), Carlos García Girón, Renata Fonseca Vianna Lopez, Isabel Sevilla, Emilio Esteban, (unknown), (unknown), (unknown), Ángel J. Lacave	3
20	Secondary Prophylactic G-CSF (Filgrastim) Administration in Chemotherapy of Stage I and II Hodgkin's Lymphoma with ABVD 2001 ·Leukemia & lymphoma ·Antonio Rueda, Isabel Sevilla, Josep Gumà, Nuria Ribelles, (unknown), (unknown), Antonia Márquez, Emilio Alba	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact